GSK6097608

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Neoplasms

Phase 1

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Active, not recruitingNCT04446351

GlaxoSmithKlineNeoplasms

Start: 2020-06-25End: 2026-12-31Updated: 2025-10-27

Phase 2

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

CompletedNCT03739710

GlaxoSmithKlineNeoplasms

Start: 2019-01-24End: 2024-05-02Updated: 2025-06-15

Related Papers

488 Phase 1 trial of first-in-class anti-CD96 monoclonal antibody inhibitor, GSK6097608, monotherapy and combination with anti–PD-1 monoclonal antibody, dostarlimab, in advanced solid tumors

Regular and Young Investigator Award Abstracts2021-11-015 citations